Freeman v. Minnesota Mining & Manufacturing Co.

675 F. Supp. 877, 5 U.S.P.Q. 2d (BNA) 1465, 10 Fed. R. Serv. 3d 1259, 1987 U.S. Dist. LEXIS 11725
District Court, D. Delaware·Decided December 17, 1987·No. Civ. A. 84-577 CMW, 85-46 CMW·Published·Cited by 5 cases

Opinion

OPINION

CALEB M. WRIGHT, Senior District Judge.

This action arises out of separate patent infringement suits filed by Dr. Jerre Freeman against CooperVision, Inc. (“CooperVision”) and Minnesota Mining and Manufacturing Company (“3M”) for infringement of Freeman’s patent relating to intraocular lenses. The suits were consolidated for the purposes of discovery and trial on the issues of validity, scope of the claims, infringement, and enforceability because of common issues of law and fact. Defendants 3M and CooperVision each filed a summary judgment motion. CooperVision subsequently filed a motion to strike an affidavit submitted by Freeman and to preclude proof on the subject matter of that affidavit. The Court denies both summary judgment motions, strikes the affidavit, but does not preclude proof.

I. FACTS

An intraocular lens (“IOL”) is an artificial lens placed within the eye to replace a damaged natural eye lens. It consists of an optical lens portion and supporting elements called haptics. The haptics serve to position the optical portion and maintain it in place. The IOL is placed in the anterior chamber of the eye. This chamber is filled with aqueous humor, a fluid with a density of approximately one.

On March 15, 1976, Freeman filed patent application number 666,651 for a “Neutral Buoyancy Intraocular Lens Device.” The patent was issued on March 7,1978, as U.S. Patent No. 4,077,071 (“ '071 patent”). On May 31, 1979, Freeman filed a reissue application. The reissue patent was issued on August 7, 1984, as U.S. Reissue Patent No. 31,640 entitled “Buoyancy Intraocular Lens Device” (“ ’640 patent” or “Freeman’s patent” or “reissue patent”).

Freeman filed suit against 3M for infringement of the '640 reissue patent on October 5,1984. He filed suit against Coo- *881 perVision on January 18, 1985. On May 20, 1985, the two cases were consolidated for trial on the issues of validity, scope of the claims, infringement, and enforceability. Damages, if any, will be the subject of separate trials. Discovery closed on October 81, 1986.

Subsequent to Freeman’s filing these suits, 3M sought to have the Patent and Trademark Office (“PTO”) reexamine the patents in light of publications that it believed anticipated the patents. On March 26, 1987, Freeman filed a Motion to Enjoin 3M from filing a petition for reexamination while the instant litigation was pending. This Court denied plaintiffs request for an injunction on April 30, 1987. Freeman v. Minnesota Mining and Mfg. Co., 661 F.Supp. 886 (D.Del.1987). The PTO granted 3M’s request for reexamination, and the proceedings are ongoing.

The defendants then filed four motions. Defendant CooperVision filed its Motion for Summary Judgment of Patent Invalidity because of prior publication on April 30, 1987 (“Motion l”). 1 It claimed that a Protocol of the Second Clinical Conference of the Moscow Experimental Laboratory for Experimental Surgery held on April 15, 1974 (“Russian Protocol” or “Protocol”), was published and shelved at the Moscow Research Institute of Eye Microsurgery (“Moscow Eye Institute”) more than one year prior to Freeman’s application for a patent. The Protocol discusses experiments performed with an IOL containing polypropylene haptics and refers to 150 having been made and 24 implanted. Patent Examiner Ronald L. Frinks was unaware of the existence of the Protocol at the time of the prosecution of the patent.

CooperVision also cites an article written by Dr. Joaquin Barraquer entitled “Nuevos Modelos de Lentes Plásticas de Camera Anterior” which appeared in Anales de Instituto Barraquer, Vol. II, No. 3 (1961) (“Barraquer Article”). Figure 15 of the Barraquer Article describes an IOL with a methacrylate optic and support members made of polyethylene, which has a density less than one. Figure 15 also states that “[tjhere are still unresolved difficulties in the injection of the mould [sic] in perfecting this model.” Patent Examiner Frinks was also unaware of this article.

In his opposition to CooperVision’s summary judgment motion, Freeman submitted the affidavit of Dr. Donald MacKeen for the proposition that the Barraquer Article could not anticipate Freeman’s patent because the device described in it was inoperable. CooperVision then filed a Motion to Strike the Affidavit of Dr. Donald MacK-een and to Preclude Proof on the issue of the inoperability of the device discussed in the Barraquer Article on June 5, 1987 (“Motion 4”).

Defendant 3M also filed two motions. On May 1, 1987, 3M filed its Motion for Partial Summary Judgment Regarding Claim Scope (“Motion 2”). On May 26, 1987, 3M filed its Motion to Lift the Confidential Status of Discovery Materials (“Motion 3”).

The Court held oral argument on all four motions on June 25,1987. Ruling from the bench, the Court granted 3M’s motion to lift the confidentiality status of certain documents. This Opinion represents the Court’s decision on the other three motions.

II. COOPERVISION’S MOTION FOR SUMMARY JUDGMENT OF PATENT INVALIDITY

CooperVision filed a Motion for Summary Judgment that Reissue Patent No. 31,-640 2 is invalid as a matter of law because the invention was disclosed in publications more than one year prior to the date of the original patent application, March 15, 1976. It claims that the Russian Protocol and the Barraquer Article, as printed publications prior to March 15, 1975, invalidate the '640 *882 reissue patent. 3 The PTO was unaware of the references. Deposition of Examiner Roland L. Frinks at 22, 25, CooperVision’s Brief in Support of Motion 1, app. 3. Because genuine issues of material fact exist as to the status of both the Russian Protocol and the Barraquer Article as invalidating references, the Court denies CooperVision’s Motion.

A. The Legal Standard

The Court’s summary judgment analysis under Rule 56 of the Federal Rules of Civil Procedure is the same in patent cases as in other types of cases. See, e.g., Howes v. Medical Components, Inc., 814 F.2d 638, 643 (Fed.Cir.1987) (summary judgment is appropriate in patent cases if no genuine issue of material fact exists). To prevail, CooperVision must demonstrate the absence of any genuine issue of material fact and prove that it is entitled to judgment as a matter of law. Fed.R.Civ.P. 56(c). The Court must resolve all ambiguities and doubts as to the existence of factual issues in favor of Freeman. Howes, 814 F.2d at 643. Therefore, to prevent summary judgment, Freeman need just “point to an evi-dentiary conflict created on the record.” Armco, Inc. v. Cyclops Corp., 791 F.2d 147, 149 (Fed.Cir.1986) (citation omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Freeman v. Minnesota Mining & Manufacturing Co., 675 F. Supp. 877, 5 U.S.P.Q. 2d (BNA) 1465, 10 Fed. R. Serv. 3d 1259, 1987 U.S. Dist. LEXIS 11725 (D. Del. 1987).

675 F. Supp. 877 (Freeman v. Minnesota Mining & Manufacturing Co.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Stender v. Vincent
992 P.2d 50 (Hawaii Supreme Court, 2000)
Chalmers v. Petty
136 F.R.D. 399 (M.D. North Carolina, 1991)
Freeman v. Minnesota Mining & Manufacturing Co.
693 F. Supp. 134 (D. Delaware, 1988)